Targets › GCK
5 programs from 5 companies in 15 trials: 11 Phase 3, 3 Phase 1, 1 Phase 2; Metabolic and endocrine, Cardiovascular, Genitourinary; next expected readout Nov 2026.
Catalyzes the phosphorylation of hexose, such as D-glucose, D-fructose and D-mannose, to hexose 6-phosphate (D-glucose 6-phosphate, D-fructose 6-phosphate and D-mannose 6-phosphate, respectively). Compared to other hexokinases, has a weak affinity for D-glucose, and is effective only when glucose is abundant (By similarity). (UniProt, P35557)
Open in Phaseline: the race on GCK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Elecoglipron Dipeptidyl peptidase-4 (DPP-4) inhibitor | DPP4, GCK, GCGR | Phase 3 | Obesity; Type 2 Diabetes Mellitus; Weight Management; Heart Failure With Preserved Ejection Fraction (HFpEF) … | Nov 2026 |
| vTv Therapeutics | Cadisegliatin Glucokinase activator | GCK | Phase 3 | Diabetes Mellitus, Type 1 | Apr 2027 |
| University of Alabama at Birmingham | Dorzagliatin Glucokinase activator | GCK | Phase 3 | Type 2 Diabetes | – |
| Chinese University of Hong Kong | Dorzagliatin Allosteric glucokinase activator | GCK | Phase 2 | Diabetes Mellitus | Dec 2026 |
| Michael R. Rickels, MD, MS | Dorzagliatin Glucokinase activator | GCK | Phase 1 | Pancreatic Insufficiency | Jul 2027 |
Type 2 Diabetes Mellitus (5) Healthy Participants (2) Obesity (1) Weight Management (1) Heart Failure With Preserved Ejection Fraction (HFpEF) (1) Chronic Kidney Disease (1) Type 2 Diabetes (1) Diabetes Mellitus (1) Pancreatic Insufficiency (1) Diabetes Mellitus, Type 1 (1)
small molecule (4), mixed (1)
AstraZeneca (1) University of Alabama at Birmingham (1) Chinese University of Hong Kong (1) Michael R. Rickels, MD, MS (1) vTv Therapeutics (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.